BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Łoboda A, Dulak J. Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future. Pharmacol Rep 2020;72:1227-63. [PMID: 32691346 DOI: 10.1007/s43440-020-00134-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Murphy S, Zweyer M, Swandulla D, Ohlendieck K. Bioinformatic Analysis of the Subproteomic Profile of Cardiomyopathic Tissue. Methods in Molecular Biology 2023. [DOI: 10.1007/978-1-0716-2831-7_26] [Reference Citation Analysis]
2 Bronisz-Budzyńska I, Kozakowska M, Pietraszek-Gremplewicz K, Madej M, Józkowicz A, Łoboda A, Dulak J. NRF2 Regulates Viability, Proliferation, Resistance to Oxidative Stress, and Differentiation of Murine Myoblasts and Muscle Satellite Cells. Cells 2022;11:3321. [PMID: 36291188 DOI: 10.3390/cells11203321] [Reference Citation Analysis]
3 Yang T, Braun M, Lembke W, Mcblane F, Kamerud J, Dewall S, Tarcsa E, Fang X, Hofer L, Kavita U, Upreti VV, Gupta S, Loo L, Johnson AJ, Chandode RK, Stubenrauch K, Vinzing M, Xia CQ, Jawa V. Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper. Molecular Therapy - Methods & Clinical Development 2022;26:471-94. [DOI: 10.1016/j.omtm.2022.07.018] [Reference Citation Analysis]
4 Marini V, Marino F, Aliberti F, Giarratana N, Pozzo E, Duelen R, Cortés Calabuig Á, La Rovere R, Vervliet T, Torella D, Bultynck G, Sampaolesi M, Chai YC. Long-term culture of patient-derived cardiac organoids recapitulated Duchenne muscular dystrophy cardiomyopathy and disease progression. Front Cell Dev Biol 2022;10:878311. [DOI: 10.3389/fcell.2022.878311] [Reference Citation Analysis]
5 Chung Liang L, Sulaiman N, Yazid MD. A Decade of Progress in Gene Targeted Therapeutic Strategies in Duchenne Muscular Dystrophy: A Systematic Review. Front Bioeng Biotechnol 2022;10:833833. [PMID: 35402409 DOI: 10.3389/fbioe.2022.833833] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Podkalicka P, Mucha O, Kaziród K, Szade K, Stępniewski J, Ivanishchuk L, Hirao H, Pośpiech E, Józkowicz A, Kupiec-Weglinski JW, Dulak J, Łoboda A. miR-378 affects metabolic disturbances in the mdx model of Duchenne muscular dystrophy. Sci Rep 2022;12:3945. [PMID: 35273230 DOI: 10.1038/s41598-022-07868-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Svetlove A, Albers J, Hülsmann S, Markus MA, Zschüntzsch J, Alves F, Dullin C. Non-Invasive Optical Motion Tracking Allows Monitoring of Respiratory Dynamics in Dystrophin-Deficient Mice. Cells 2022;11:918. [PMID: 35269540 DOI: 10.3390/cells11050918] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Marini V, Marino F, Aliberti F, Giarratana N, Pozzo E, Duelen R, Calabuig ÁC, Larovere R, Vervliet T, Torella D, Bultynck G, Sampaolesi M, Chai YC. Long-Term Culture of Patient-Derived Cardiac Organoids Recapitulated Duchenne Muscular Dystrophy Cardiomyopathy and Disease Progression.. [DOI: 10.1101/2022.02.25.481935] [Reference Citation Analysis]
9 Schneider SM, Sansom GT, Guo L, Furuya S, Weeks BR, Kornegay JN. Natural History of Histopathologic Changes in Cardiomyopathy of Golden Retriever Muscular Dystrophy. Front Vet Sci 2022;8:759585. [DOI: 10.3389/fvets.2021.759585] [Reference Citation Analysis]
10 Chen N, Sun K, Chemuturi NV, Cho H, Xia CQ. The Perspective of DMPK on Recombinant Adeno-Associated Virus-Based Gene Therapy: Past Learning, Current Support, and Future Contribution. AAPS J 2022;24:31. [PMID: 35102450 DOI: 10.1208/s12248-021-00678-7] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Sattenapalli NC, Areti AR, G. SKR, Kulandaivelu US, Alavala RR, Manne R. Study of Clinical Features and Diagnosis Pattern of Duchene Muscular Dystrophy in Southern India. J Neurosci Rural Pract. [DOI: 10.1055/s-0041-1740614] [Reference Citation Analysis]
12 Jablonka S, Hennlein L, Sendtner M. Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders. Neurol Res Pract 2022;4:2. [PMID: 34983696 DOI: 10.1186/s42466-021-00162-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Mucha O, Kaziród K, Podkalicka P, Rusin K, Dulak J, Łoboda A. Dysregulated Autophagy and Mitophagy in a Mouse Model of Duchenne Muscular Dystrophy Remain Unchanged Following Heme Oxygenase-1 Knockout. Int J Mol Sci 2021;23:470. [PMID: 35008897 DOI: 10.3390/ijms23010470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Bekhite MM, Schulze PC. Human Induced Pluripotent Stem Cell as a Disease Modeling and Drug Development Platform-A Cardiac Perspective. Cells 2021;10:3483. [PMID: 34943991 DOI: 10.3390/cells10123483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Mucha O, Podkalicka P, Kaziród K, Samborowska E, Dulak J, Łoboda A. Simvastatin does not alleviate muscle pathology in a mouse model of Duchenne muscular dystrophy. Skelet Muscle 2021;11:21. [PMID: 34479633 DOI: 10.1186/s13395-021-00276-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
16 Willis T. Recent advances in the treatment of Duchenne muscular dystrophy. Paediatrics and Child Health 2021;31:359-363. [DOI: 10.1016/j.paed.2021.06.005] [Reference Citation Analysis]
17 Shen OY, Chen YF, Xu HT, Lee CW. The Efficacy of Naïve versus Modified Mesenchymal Stem Cells in Improving Muscle Function in Duchenne Muscular Dystrophy: A Systematic Review. Biomedicines 2021;9:1097. [PMID: 34572283 DOI: 10.3390/biomedicines9091097] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
18 Boyer O, Butler-Browne G, Chinoy H, Cossu G, Galli F, Lilleker JB, Magli A, Mouly V, Perlingeiro RCR, Previtali SC, Sampaolesi M, Smeets H, Schoewel-Wolf V, Spuler S, Torrente Y, Van Tienen F; Study Group. Myogenic Cell Transplantation in Genetic and Acquired Diseases of Skeletal Muscle. Front Genet 2021;12:702547. [PMID: 34408774 DOI: 10.3389/fgene.2021.702547] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
19 Krishnan SM, Nordlohne J, Dietz L, Vakalopoulos A, Haning P, Hartmann E, Seifert R, Hüser J, Mathar I, Sandner P. Assessing the Use of the sGC Stimulator BAY-747, as a Potential Treatment for Duchenne Muscular Dystrophy. Int J Mol Sci 2021;22:8016. [PMID: 34360780 DOI: 10.3390/ijms22158016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Florczyk-Soluch U, Polak K, Dulak J. The multifaceted view of heart problem in Duchenne muscular dystrophy. Cell Mol Life Sci 2021;78:5447-68. [PMID: 34091693 DOI: 10.1007/s00018-021-03862-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
21 Hamilton BA, Wright JF. Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes. Front Immunol 2021;12:675897. [PMID: 34084173 DOI: 10.3389/fimmu.2021.675897] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
22 Palacios-espinosa X, Vera-márquez ÁV, Mateus H, Dávalos Serrano ML, Gracia-ruiz J, Huertas JF. Experiences of caregivers of boys with Duchenne Muscular Dystrophy. Interd 2021;38:221-238. [DOI: 10.16888/interd.2021.38.3.13] [Reference Citation Analysis]
23 Podkalicka P, Mucha O, Kaziród K, Bronisz-Budzyńska I, Ostrowska-Paton S, Tomczyk M, Andrysiak K, Stępniewski J, Dulak J, Łoboda A. Age-Dependent Dysregulation of Muscle Vasculature and Blood Flow Recovery after Hindlimb Ischemia in the mdx Model of Duchenne Muscular Dystrophy. Biomedicines 2021;9:481. [PMID: 33925757 DOI: 10.3390/biomedicines9050481] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
24 Starosta A, Konieczny P. Therapeutic aspects of cell signaling and communication in Duchenne muscular dystrophy. Cell Mol Life Sci 2021;78:4867-91. [PMID: 33825942 DOI: 10.1007/s00018-021-03821-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
25 Andrysiak K, Stępniewski J, Dulak J. Human-induced pluripotent stem cell-derived cardiomyocytes, 3D cardiac structures, and heart-on-a-chip as tools for drug research. Pflugers Arch 2021;473:1061-85. [PMID: 33629131 DOI: 10.1007/s00424-021-02536-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 18.0] [Reference Citation Analysis]
26 Fortunato F, Rossi R, Falzarano MS, Ferlini A. Innovative Therapeutic Approaches for Duchenne Muscular Dystrophy. J Clin Med 2021;10:820. [PMID: 33671409 DOI: 10.3390/jcm10040820] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 17.0] [Reference Citation Analysis]
27 Rodriguez-Gonzalez M, Lubian-Gutierrez M, Cascales-Poyatos HM, Perez-Reviriego AA, Castellano-Martinez A. Role of the Renin-Angiotensin-Aldosterone System in Dystrophin-Deficient Cardiomyopathy. Int J Mol Sci 2020;22:E356. [PMID: 33396334 DOI: 10.3390/ijms22010356] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
28 Choi A, Park SE, Jeong JB, Choi SJ, Oh SY, Ryu GH, Lee J, Jeon HB, Chang JW. Anti-Fibrotic Effect of Human Wharton's Jelly-Derived Mesenchymal Stem Cells on Skeletal Muscle Cells, Mediated by Secretion of MMP-1. Int J Mol Sci 2020;21:E6269. [PMID: 32872523 DOI: 10.3390/ijms21176269] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]